生物活性 | |||
---|---|---|---|
描述 | AXC-715 (T785) trihydrochloride, a TLR7/TLR8 dual agonist, is derived from patent WO2020168017 A1 [1]. AXC-715 trihydrochloride, also known as compound D from WO2020190734A1, serves for synthesizing antibody-adjuvant immunoconjugates, composed of an antibody construct binding programmed death-ligand 1 (PD-L1) linked to one or more adjuvants [2]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.38mL 0.48mL 0.24mL |
11.88mL 2.38mL 1.19mL |
23.76mL 4.75mL 2.38mL |
参考文献 |
---|
[2]Shelley Erin ACKERMAN, et al. Immunoconjugates targeting pd-l1. Patent WO2020190734A1. |